Heparin-induced thrombocytopenia and the anesthesiologist

Canadian Journal of Anesthesia

Volumn 49, Issue 6, 2002, Pages

  Warkentin, Theodore E ^a  

^a HAMILTON REGIONAL LABORATORY MEDICINE PROGRAM   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANCROD; ANTIBODY; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ARGATROBAN; DANAPAROID; DIPYRIDAMOLE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; ILOPROST; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; PROSTACYCLIN; PROTAMINE; TIROFIBAN;

ANESTHESIST; ANTIBODY DETECTION; ANTIBODY PRODUCTION; ANTICOAGULATION; ARTICLE; BLOOD CLOTTING; BOLUS INJECTION; CENTRAL VENOUS CATHETERIZATION; DEEP VEIN THROMBOSIS; DRUG ELIMINATION; DRUG EXPOSURE; DRUG HALF LIFE; EXPERIENCE; HEART ARREST; HEART SURGERY; HUMAN; INTRAOPERATIVE PERIOD; MEDICAL LITERATURE; PARTIAL THROMBOPLASTIN TIME; PATIENT MONITORING; PRIORITY JOURNAL; RESPIRATORY ARREST; SURGICAL PATIENT; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOSIS; VASCULAR SURGERY; ANESTHESIA; CHEMICALLY INDUCED DISORDER; REVIEW;

ANESTHESIA; ANTICOAGULANTS; CARDIAC SURGICAL PROCEDURES; HEPARIN; HUMAN; PLATELET AGGREGATION INHIBITORS; SUPPORT, NON-U.S. GOV'T; THROMBOCYTOPENIA; VASCULAR SURGICAL PROCEDURES; HUMANS;

EID: 0036600013     PISSN: 0832610X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (84)

1. Heparin-induced thrombocytopenia in patients treated with low- molecular-weight heparin or unfractionated heparin
2. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia
3. Heparin-induced thrombocytopenia: Laboratory studies
4. Heparin-induced thrombocytopenia: New evidence for the dynamic binding of purified anti-PF4-heparin antibodies to platelets and the resultant platelet activation
5. The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia
6. Clinical picture of heparin-induced thrombocytopenia
7. Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: An explanation for the thrombotic complications of heparin-induced thrombocytopenia
8. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells
9. Antibodies from patients with heparin-induced thrombocytopenia stimulate monocytic cells to express tissue factor and secrete interleukin-8
10. A 14-year study of heparin-induced thrombocytopenia
11. Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia
12. Temporal aspects of heparin-induced thrombocytopenia
13. Use of heparin during cardiopulmonary bypass in patients with a history of heparin-induced thrombocytopenia
14. Acute adrenal insufficiency secondary to heparin-induced thrombocytopenia-thrombosis syndrome
15. Frequency of heparin-induced thrombocytopenia
16. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia
17. Treatment of heparin-induced thrombocytopenia: An overview
18. Heparin-induced thrombocytopenia: Yet another treatment paradox?
19. Impact of the patient population on the risk for heparin-induced thrombocytopenia
20. Venous thromboembolism during pregnancy: A retrospective study of enoxaparin safety in 624 pregnancies
21. Heparin-induced thrombocytopenia and thrombosis: A prospective analysis of the incidence in patients with heart and cerebrovascular diseases
22. Choosing a parenteral anticoagulant agent
23. Laboratory testing for heparin-induced thrombocytopenia
24. Laboratory testing for heparin-induced thrombocytopenia
25. Determination of heparin-platelet 4-IgG antibodies improves diagnosis of heparin-induced thrombocytopenia
26. Patients treated with unfractionated heparin during open heart surgery are at high risk to form antibodies reactive with heparin: Platelet factor 4 complexes
27. Prevalence of heparin-associated antibodies without thrombosis in patients undergoing cardiopulmonary bypass surgery
28. Heparin induced thrombocytopenia: A prospective study
29. Thrombocytopenia in a prospective, randomized, double blind trial of bovine and porcine heparin
30. Studies on the frequency of heparin-associated thrombocytopenia
31. Heparin-associated thrombocytopenia: A prospective comparison of bovine lung heparin, manufactured by new process, and porcine intestinal heparin
32. A randomized study of beef lung and pork mucosal heparin in cardiac surgery
33. Porcine heparin increases postoperative bleeding in cardiopulmonary bypass patients
34. Heparin-induced thrombocytopenia: Bovine versus porcine heparin in cardiopulmonary bypass surgery
35. Comparative effects of bovine and porcine heparin on heparin antibody formation following cardiovascular surgery
36. Delayed-onset heparin-induced thrombocytopenia and thrombosis
37. Delayed-onset heparin-induced thrombocytopenia
38. Intraoperative heparin flushes and subsequent acute heparin-induced thrombocytopenia
39. 'Incidental' unfractionated heparin (UFH) vs normal saline (NS) flushes for intraoperative invasive catheters and the frequency of formation of heparin-induced thrombocytopenia IgG antibodies (HIT-IgG): A randomized, controlled trial
40. Frequency of upper limb deep venous thrombosis (UL-DVT) in relation to central venous catheter (CVC) use in patients with heparin-induced systemic (HIT) and local (CVC) prothrombotic risk factors
41. Heparin-induced thrombocytopenia, Part 1: The diagnostic clues
42. Pseudopulmonary embolism: Acute respiratory distress in the syndrome of heparin-induced thrombocytopenia
43. Heparin-induced thrombocytopenia (HIT) due to heparin flushes: A report of three cases
44. Heparin-induced thrombocytopenia, thrombosis, and hemorrhage
45. Pseudo-heparin-induced thrombocytopenia
46. Cardiopulmonary bypass for patients with previously documented heparin-induced platelet aggregation
47. Management of cardiopulmonary bypass anticoagulation in patients with heparin-induced thrombocytopenia
48. Emergency cardiopulmonary bypass in a bilaterally nephrectomized patient with a history of heparin-induced thrombocytopenia: Successful reexposure to heparin
49. Iloprost (ZK36374), a new prostacyclin analogue, permits open cardiac surgery in patients with heparin-induced thrombocytopenia
50. Prevention of heparin-induced thrombocytopenia during open heart surgery with iloprost (ZK36374)
51. Heparin-associated thrombocytopenia: Management of patients for open heart surgery. Case reports describing the use of iloprost
52. Cardiac surgery with cardiopulmonary bypass in patients with type II heparin-induced thrombocytopenia
53. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension
54. Cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia II and impaired renal function using heparin and the platelet GP IIb/IIIa inhibitor tirofiban as anticoagulant
55. Anticoagulation during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II and renal impairment using heparin and the platelet glycoprotein IIb-IIIa antagonist tirofiban
56. One-year experience with the platelet glycoprotein IIb/IIIa antagonist tirofiban and heparin during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II
57. Tirofiban. A review of its use in acute coronary syndromes
58. Cardiopulmonary bypass in patients with heparin-induced thrombocytopenia and thrombosis
59. Alternatives to unfractionated heparin for anticoagulation in cardiopulmonary bypass
60. Management of patients with heparin-induced thrombocytopenia requiring cardiopulmonary bypass
61. Extracorporeal circulation in a patient with heparin induced thrombocytopenia
62. Management of patients with heparin associated thrombocytopenia and thrombosis requiring cardiac surgery
63. Carotid endarterectomy in patients with heparin induced platelet activation: Comparative efficacy of aspirin and iloprost (ZK36374)
64. Newer strategies for the treatment of heparin induced thrombocytopenia
65. Danaparoid for the treatment of heparin-induced thrombocytopenia
66. Orgaran anticoagulation for cardiopulmonary bypass in patients with heparin-induced thrombocytopenia
67. Intraoperative monitoring of danaparoid sodium anti-coagulation during cardiovascular operations
68. Use of danaparoid during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia
69. Use of danaparoid sodium (Orgaran) as an alternative to heparin sodium during cardiopulmonary bypass: A clinical evaluation of six cases
70. Off-pump coronary artery bypass grafting for acute heparin-induced thrombocytopenia
71. Recombinant hirudin for the treatment of heparin-induced thrombocytopenia
72. Recombinant hirudin in clinical practice: Focus on lepirudin
73. Recombinant hirudin as an anti-coagulant during cardiopulmonary bypass-assessment of the whole blood ecarin clotting time
74. The relationship between hirudin and activated clotting time: Implications for patients with heparin-induced thrombocytopenia undergoing cardiac surgery
75. Use of ecarin clotting time (ECT) with lepirudin therapy in heparin-induced thrombocytopenia and cardiopulmonary bypass
76. Ecarin clotting time: A new tool for management of heparin induced thrombocytopenia in cardiac surgery
77. Hirudin monitoring using the TAS ecarin clotting time in patients with heparin-induced thrombocytopenia type II
78. Argatroban therapy in heparin-induced thrombocytopenia
79. Experimental evaluation of argatroban for cardiopulmonary bypass
80. Argatroban as a potential anticoagulant in cardiopulmonary bypass- studies in a dog model
81. The use of argatroban as an anticoagulant for cardiopulmonary bypass in cardiac operations
82. Rapid anticoagulation using ancrod for heparin-induced thrombocytopenia
83. Ancord (Arvin) as an alternative to heparin anticoagulation for cardiopulmonary bypass
84. Clinical experience of argatroban for anticoagulation in cardiovascular surgery